Skip to main content

Drug Interactions between antivenin (black widow spider) and Betagan C-Cap

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

antivenin (black widow spider) levobunolol ophthalmic

Applies to: antivenin (black widow spider) and Betagan C-Cap (levobunolol ophthalmic)

MONITOR: Beta-adrenergic blockers (including ophthalmic formulations) may increase the severity and duration of acute anaphylactic reactions to antivenins. In addition, anaphylaxis may be resistant to the usual treatment modalities. The mechanism is unknown.

MANAGEMENT: Patients should be closely monitored for signs of severe, acute hypersensitivity reactions during administration of antivenins, and facilities and equipment for resuscitation, cardiovascular support, and airway management should be immediately available. Clinicians should be aware that larger doses of epinephrine or other adrenergic agents may be required.

References

  1. "Product Information. CroFab (antivenin (Crotalidae) polyvalent)." Savage Laboratories PROD
  2. "Product Information. Antivenin (Latrodectus mactans) (antivenin (black widow spider))." Merck & Co., Inc (2022):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer